The treatment and survival of elderly patients with locally advanced pancreatic cancer: A post-hoc analysis of a multicenter registry

L.J.H. Brada*, M.S. Walma, R.M. van Dam, J. de Vos-Geelen, I.H. de Hingh, G.J. Creemers, M.S. Liem, L.J. Mekenkamp, V.E. de Meijer, D.J.A. de Groot, G.A. Patijn, J.W.B. de Groot, S. Festen, E.D. Kerver, M.W.J. Stommel, M.R. Meijerink, K. Bosscha, J.F. Pruijt, M.B. Polee, J.A. RopelaG.A. Cirkel, M. Los, J.W. Wilmink, N.H. Mohammad, H.C. van Santvoort, M.G. Besselink, I.Q. Molenaar*, Dutch Pancreatic Canc Grp

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

4 Citations (Web of Science)
Original languageEnglish
Pages (from-to)163-169
Number of pages7
JournalPancreatology
Volume21
Issue number1
DOIs
Publication statusPublished - 1 Jan 2021

Keywords

  • adenocarcinoma
  • age
  • best supportive care
  • chemotherapy
  • comorbidity
  • disparities
  • elderly
  • folfirinox
  • gemcitabine
  • locally advanced pancreatic cancer
  • nab-paclitaxel
  • older patients
  • outcomes
  • Best supportive care
  • FOLFIRINOX
  • NAB-PACLITAXEL
  • COMORBIDITY
  • AGE
  • ADENOCARCINOMA
  • GEMCITABINE
  • CHEMOTHERAPY
  • Chemotherapy
  • OLDER PATIENTS
  • DISPARITIES
  • Locally advanced pancreatic cancer
  • OUTCOMES
  • Elderly

Cite this